Loading
InnoPharmax is a Taiwanese pharmaceutical company running phase 3 trials of D07001, its oral formulation of the chemotherapy irinotecan, in biliary tract cancer.
InnoPharmax, based in Taipei, develops oral formulations of established cancer drugs. Its lead programme D07001 is an oral form of irinotecan designed to allow outpatient dosing, in phase 3 trials for advanced biliary tract cancer after first-line chemotherapy. Sponsor and trial facts are from the ClinicalTrials.gov registry.
D07001 is an experimental small-molecule drug from InnoPharmax in phase 3 trials for biliary tract cancer, with its target not yet stated publicly.